复发性铂耐药卵巢癌的靶向治疗：现有和新兴疗法。
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
机构信息
Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Cancer Manag Res. 2011;3:25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.
Abstract
With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. Prognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respond to available therapies. Emerging treatment strategies have sub-sequently focused on targets which are integral to tumor growth and metastasis. In this review, we will focus on those innovative agents currently under investigation in clinical trials.
摘要
随着外科技术和化疗药物的进步，上皮性卵巢癌 (EOC) 的死亡率在过去 30 年中略有下降。然而，EOC 仍然是最致命的妇科癌症，总体 5 年生存率为 45%。对于铂类耐药疾病的女性，预后尤其令人失望，其中 80%的患者对现有治疗方法无反应。新出现的治疗策略随后集中在对肿瘤生长和转移至关重要的靶点上。在这篇综述中，我们将重点介绍目前正在临床试验中研究的那些创新药物。
相似文献
1
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.复发性铂耐药卵巢癌的靶向治疗：现有和新兴疗法。
Cancer Manag Res. 2011;3:25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30.
2
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.铂耐药-铂难治性卵巢癌的治疗简要综述。
Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25.
3
Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.曲贝替定（AMG 386）治疗上皮性卵巢癌的疗效。
Expert Opin Pharmacother. 2016;17(6):853-60. doi: 10.1517/14656566.2016.1161027. Epub 2016 Mar 21.
4
Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives.免疫疗法在铂耐药卵巢癌治疗中的应用现状
Onco Targets Ther. 2022 Aug 10;15:853-866. doi: 10.2147/OTT.S335936. eCollection 2022.
5
Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.复发性低级别上皮性卵巢癌患者的生存和预后因素：NOGGO 元数据库的五项前瞻性 II/III 期试验分析。
Gynecol Oncol. 2019 Sep;154(3):539-546. doi: 10.1016/j.ygyno.2019.06.014. Epub 2019 Jun 21.
6
Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.低剂量口服依托泊苷治疗复发性铂耐药上皮性卵巢癌患者的疗效
J Obstet Gynaecol. 2017 Jul;37(5):649-654. doi: 10.1080/01443615.2017.1290056. Epub 2017 Mar 21.
7
Optimal chemotherapy treatment for women with recurrent ovarian cancer.复发性卵巢癌女性的最佳化疗治疗。
Curr Oncol. 2007 Oct;14(5):195-208. doi: 10.3747/co.2007.148.
8
Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.铂类敏感复发性卵巢癌的新型治疗选择：综述。
Gynecol Oncol. 2019 Feb;152(2):416-425. doi: 10.1016/j.ygyno.2018.10.023. Epub 2018 Nov 5.
9
Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic.上皮性卵巢癌的新型靶向治疗：从基础研究到临床应用
Expert Rev Endocrinol Metab. 2007 Mar;2(2):225-238. doi: 10.1586/17446651.2.2.225.
10
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.贝伐单抗治疗铂耐药卵巢癌的概况：当前观点
Int J Womens Health. 2016 Mar 15;8:59-75. doi: 10.2147/IJWH.S78101. eCollection 2016.
引用本文的文献
1
Aptamer-Coated PLGA Nanoparticles Selectively Internalize into Epithelial Ovarian Cancer Cells In Vitro and In Vivo.适体包被的聚乳酸-羟基乙酸共聚物纳米颗粒在体外和体内均可选择性内化进入上皮性卵巢癌细胞。
Biomolecules. 2025 Aug 4;15(8):1123. doi: 10.3390/biom15081123.
2
Exploration of chemotherapy-free regimen after multi-line chemotherapy-induced renal impairment in recurrent ovarian cancer: Case report and literature review.复发性卵巢癌多线化疗致肾功能损害后无化疗方案的探索：病例报告与文献综述
Front Oncol. 2023 Jan 19;12:1031045. doi: 10.3389/fonc.2022.1031045. eCollection 2022.
3
New progress of glutamine metabolism in the occurrence, development, and treatment of ovarian cancer from mechanism to clinic.谷氨酰胺代谢在卵巢癌发生、发展及治疗中从机制到临床的新进展
Front Oncol. 2022 Nov 29;12:1018642. doi: 10.3389/fonc.2022.1018642. eCollection 2022.
4
circANKRD17(has_circ_0007883) confers paclitaxel resistance of ovarian cancer via interacting with FUS to stabilize FOXR2.环状ANKRD17（即circ_0007883）通过与FUS相互作用以稳定FOXR2，赋予卵巢癌对紫杉醇的抗性。
Mol Cell Biochem. 2023 Apr;478(4):835-850. doi: 10.1007/s11010-022-04548-4. Epub 2022 Sep 15.
5
CpG-binding protein CFP1 promotes ovarian cancer cell proliferation by regulating BST2 transcription.CpG 结合蛋白 CFP1 通过调控 BST2 转录促进卵巢癌细胞增殖。
Cancer Gene Ther. 2022 Dec;29(12):1895-1907. doi: 10.1038/s41417-022-00503-z. Epub 2022 Jul 21.
6
Effectiveness of psychoeducation intervention among women with gynecological cancer: a systematic review and meta-analysis of randomized controlled trials.妇科癌症女性患者心理教育干预的效果：随机对照试验的系统评价和荟萃分析。
Support Care Cancer. 2022 Oct;30(10):8271-8285. doi: 10.1007/s00520-022-07277-y. Epub 2022 Jul 12.
7
Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.联合抑制 IL-6 和 IL-8 通路可抑制卵巢癌细胞活力、迁移和肿瘤生长。
Int J Oncol. 2022 May;60(5). doi: 10.3892/ijo.2022.5340. Epub 2022 Mar 22.
8
The gene predicts prognosis and response to chemotherapy in epithelial ovarian cancer.该基因可预测上皮性卵巢癌的预后及对化疗的反应。
Ann Transl Med. 2021 May;9(9):806. doi: 10.21037/atm-21-2087.
9
Promoter Methylation of the Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients.基因的启动子甲基化可预测高级别浆液性卵巢癌患者的预后及对化疗的反应。
Front Oncol. 2021 Jun 29;11:659254. doi: 10.3389/fonc.2021.659254. eCollection 2021.
10
Immunotherapy Advances for Epithelial Ovarian Cancer.上皮性卵巢癌的免疫治疗进展
Cancers (Basel). 2020 Dec 11;12(12):3733. doi: 10.3390/cancers12123733.
本文引用的文献
1
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.西普利单抗免疫治疗去势抵抗性前列腺癌。
N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.
2
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.一项舒尼替尼治疗复发性上皮性卵巢癌和原发性腹膜癌患者的 II 期研究：加拿大国立癌症研究所临床试验组研究。
Ann Oncol. 2011 Feb;22(2):335-40. doi: 10.1093/annonc/mdq357. Epub 2010 Aug 12.
3
A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).一项厄洛替尼（OSI-774）联合卡铂治疗复发性上皮性卵巢癌（NCIC CTG IND.149）的 II 期研究。
Gynecol Oncol. 2010 Sep;118(3):308-12. doi: 10.1016/j.ygyno.2010.05.005. Epub 2010 Jun 19.
4
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.奥拉帕利在携带 BRCA1 或 BRCA2 突变的复发性卵巢癌患者中的疗效：一项概念验证试验。
Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6.
5
Targeted trials in ovarian cancer.卵巢癌的靶向临床试验。
Gynecol Oncol. 2010 Oct;119(1):151-6. doi: 10.1016/j.ygyno.2010.05.008. Epub 2010 Jun 29.
6
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.一项评估帕唑帕尼在复发性卵巢癌患者中的 II 期、开放标签研究。
Gynecol Oncol. 2010 Oct;119(1):32-7. doi: 10.1016/j.ygyno.2010.05.033. Epub 2010 Jun 27.
7
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.BRCAness 的基因表达谱与上皮性卵巢癌患者对化疗的反应性和预后相关。
J Clin Oncol. 2010 Aug 1;28(22):3555-61. doi: 10.1200/JCO.2009.27.5719. Epub 2010 Jun 14.
8
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.多柔比星脂质体与托泊替康联合治疗复发性卵巢癌。
J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1.
9
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.三功能抗体 catumaxomab 治疗上皮癌恶性腹水：前瞻性随机 2/3 期试验结果。
Int J Cancer. 2010 Nov 1;127(9):2209-21. doi: 10.1002/ijc.25423.
10
Ovarian cancer immunotherapy: opportunities, progresses and challenges.卵巢癌免疫治疗：机遇、进展与挑战。
J Hematol Oncol. 2010 Feb 10;3:7. doi: 10.1186/1756-8722-3-7.
Zotero 插件